An open-label, randomized, crossover study of comparative pharmacokinetics and bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg versus the combined use of Forxiga™, 10 mg and two Glucophage® Long, ER tablets, 500 mg co-administered to healthy volunteers under standard fed conditions

Trial Identifier: D1691C00012
Sponsor: AstraZeneca
NCTID:: NCT02722239
Start Date: March 2016
Primary Completion Date: May 2016
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Russian Translation

Trial Locations

Country Location
Russian Federation Moscow, Russian Federation, 123423